<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4848">
  <stage>Registered</stage>
  <submitdate>2/06/2014</submitdate>
  <approvaldate>2/06/2014</approvaldate>
  <nctid>NCT02155647</nctid>
  <trial_identification>
    <studytitle>Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)</studytitle>
    <scientifictitle>A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-000445-79</secondaryid>
    <secondaryid>100070-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Merkel Cell</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Avelumab

Experimental: Avelumab - 


Treatment: drugs: Avelumab
Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part A: Confirmed Best Overall Response (BOR) - BOR is defined as the confirmed best response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as determined by Independent Endpoint Review Committee (IERC), obtained from start of study drug until documented disease progression, assessed every 6 weeks. CR or PR must be confirmed by a subsequent tumor assessment preferably at the next scheduled 6-weekly assessment, but no sooner than 5 weeks after the initial documentation of CR or PR.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part B: Durable Response - Durable response is defined as objective response (complete response [CR] or partial response [PR]) according to RECIST 1.1, determined by an IERC, with a duration of at least 6 months</outcome>
      <timepoint>Up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Duration of response - Duration of response is defined as time from first observation of response (CR or PR) until first observation of documented disease progression or death when death occurs within 12 weeks of the last tumor assessment whichever occurs first.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Progression-Free Survival (PFS) Time - PFS time is defined as the time from first administration of study drug until first observation of disease progression or death when death occurs within 12 weeks of the last tumor assessment whichever occurs first.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Overall Survival (OS) Time - OS time is defined as the time from first administration of study drug until date of death.</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0</outcome>
      <timepoint>Baseline up to 90 days after last dose administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Number of subjects with anti-avelumab antibodies</outcome>
      <timepoint>Up to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Concentration at the end of infusion on Day 1</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Trough concentrations</outcome>
      <timepoint>Day 15, 29, 43, 85, 127, 169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Confirmed Best Overall Response (BOR) - BOR is defined as the confirmed best response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as determined by Independent Endpoint Review Committee (IERC).</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Duration of response - Duration of response will be according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as determined by Independent Endpoint Review Committee (IERC).</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Progression-Free Survival (PFS) Time - PFS will be according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as determined by Independent Endpoint Review Committee (IERC).</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Overall Survival (OS) Time</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0</outcome>
      <timepoint>Baseline up to 90 days after last dose administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Number of subjects with anti-avelumab antibodies</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Concentration at the end of infusion on Day 1</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Trough concentrations</outcome>
      <timepoint>Day 15, 29, 43, 85, 127, 169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Number of Subjects With Response Status According to RECIST 1.1 as Determined by an IERC</outcome>
      <timepoint>Month 6, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Number of Subjects With Response Status According to RECIST 1.1 as Determined by an IERC</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed written informed consent

          -  Age 18 years and above

          -  Histologically proven MCC

          -  Subjects must have received at least 1 line of chemotherapy for metastatic MCC and
             must have progressed after the most recent line of chemotherapy

          -  For Part B - Subjects must not have received any prior systemic treatment for
             metastatic MCC. Prior chemotherapy treatment in the adjuvant setting (no clinically
             detectable disease; no metastatic disease) is allowable if the end of treatment
             occurred at least 6 months prior to study start)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST
             Version 1.1 (including skin lesions)

          -  Adequate hematological, hepatic and renal function (renal function considered adequate
             as per protocol definition)

          -  Highly effective contraception for both male and female subjects, if the risk of
             conception exists

          -  Fresh Biopsy or Archival Tumor Tissue

          -  Estimated life expectancy of more than 12 weeks</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participation in another interventional clinical trial within the past 30 days
             (participation in observational studies is permitted)

          -  Concurrent treatment with a non permitted drug

          -  Prior therapy with any antibody/drug targeting T-cell coregulatory proteins (immune
             checkpoints) such as antiprogrammed death 1 (PD-1), anti-PD-L1, or anticytotoxic
             T-lymphocyte antigen-4 (CTLA-4) antibody; for Part B, the Investigator must consult
             with the Medical Monitor and consider other co-regulatory targets such as 4-1BB

          -  Concurrent anticancer treatment (for example, cytoreductive therapy, radiotherapy
             [with the exception of palliative bone-directed radiotherapy, or radiotherapy
             administered on non-target superficial lesions], immune therapy, or cytokine therapy
             except for erythropoietin). Radiotherapy administered to superficial lesions is not
             allowed if such lesions are considered target lesions in the efficacy evaluation or
             may influence the efficacy evaluation of the investigational agent

          -  Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the
             subject has not fully recovered from the surgery within 4 weeks

          -  Concurrent systemic therapy with steroids or other immunosuppressive agents, or use of
             any investigational drug within 28 days before the start of trial treatment.
             Short-term administration of systemic steroids (that is, for allergic reactions or the
             management of immune-related adverse events [irAE]) while on study is allowed. Also,
             subjects requiring hormone replacement with corticosteroids for adrenal insufficiency
             are eligible if the steroids are administered only for the purpose of hormonal
             replacement and at doses &lt;= 10 mg or equivalent prednisone per day. Note: Subjects
             receiving bisphosphonate or denosumab are eligible.

          -  Subjects with active central nervous system (CNS) metastases are excluded. Subjects
             with a history of treated CNS metastases (by surgery or radiation therapy) are not
             eligible unless they have fully recovered from treatment, demonstrated no progression
             for at least 2 months, and do not require continued steroid therapy

          -  Previous malignant disease (other than MCC) within the last 5 years with the exception
             of basal or squamous cell carcinoma of the skin and for Part A cervical carcinoma in
             situ or for Part B carcinoma in situ (skin, bladder, cervical, colorectal, breast or
             low grade prostatic intraepithelial neoplasia or Grade 1 prostate cancer)

          -  Prior organ transplantation, including allogeneic stem-cell transplantation

          -  Part A: Known history of testing positive for HIV or known acquired immunodeficiency
             syndrome (AIDS) or any positive test for hepatitis B virus or hepatitis C virus
             indicating acute or chronic infection. For Part B, known history of testing positive
             for HIV or known AIDS in consultation with the Medical Monitor or HBV or HCV infection
             at screening (positive HBV surface antigen or HCV RNA if anti- HCV antibody screening
             test positive).

          -  Active or history of any autoimmune disease (except for subjects with vitiligo) or
             immunodeficiencies that required treatment with systemic immunosuppressive drugs

          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade greater than
             or equal to (&gt;=) 3 NCI CTCAE v 4.0), any history of anaphylaxis, or uncontrolled
             asthma (that is, 3 or more features of partially controlled asthma)

          -  Persisting toxicity related to prior therapy Grade &gt; 1 NCI-CTCAE v 4.0; however,
             sensory neuropathy Grade &lt;= 2 is acceptable 14. Pregnancy or lactation

          -  Known alcohol or drug abuse

          -  Clinically significant (that is, active) cardiovascular disease: cerebral vascular
             accident / stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months
             prior to enrollment), unstable angina, congestive heart failure (New York Heart
             Association Classification Class &gt;= II), or serious cardiac arrhythmia requiring
             medication

          -  All other significant diseases (for example, inflammatory bowel disease), which, in
             the opinion of the Investigator, might impair the subject's tolerance of trial
             treatment

          -  Any psychiatric condition that would prohibit the understanding or rendering of
             informed consent

          -  Legal incapacity or limited legal capacity

          -  Non oncology vaccine therapies for prevention of infectious disease (for example,
             seasonal flu vaccine, human papilloma virus vaccine) within 4 weeks of trial drug
             administration. Vaccination while on trial is also prohibited except for
             administration of inactivated vaccines (for example, inactivated seasonal influenza
             vaccine)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>3/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2025</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Lismore Base Hospital - Lismore</hospital>
    <hospital>Port Macquarie Base Hospital - Port Macquarie</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Tasman Oncology Research Ltd - Southport</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville South</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>St John of God Subiaco Hospital - Perth</hospital>
    <postcode>2480 - Lismore</postcode>
    <postcode>2444 - Port Macquarie</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode> - Southport</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>3128 - East Melbourne</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Alpes Maritimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bouches-du-Rhône</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Doubs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Hauts de Seine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Loire Atlantique</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nord</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rhone</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Val de Marne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lower Saxony</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Thueringen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Perugia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka-Ken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo-To</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>EMD Serono</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the
      efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02155647</trialwebsite>
    <publication>Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Responsible</name>
      <address>Merck KGaA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>US Medical Information</name>
      <address />
      <phone>888-275-7376</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>